Physician profile
Ajay E Chitkara
NPI 1902818842
$4,375.99
in general payments reported to CMS, 2019-2025
31 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $241 · 2021: $240 · 2022: $430 · 2023: $885 · 2024: $1,143 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $808.94 | 2019-2025 | Nucala |
| Inspire Medical Systems, INC. | $666.51 | 2023-2025 | Inspire |
| Optinose US, INC. | $617.72 | 2021-2025 | |
| Stryker Corporation | $510.15 | 2019-2025 | Clarifix, Hemopore, Core |
| Regeneron Healthcare Solutions, INC. | $374.17 | 2022-2025 | Dupixent |
| Genzyme Corporation | $197.97 | 2020-2025 | |
| Genentech USA, INC. | $112.33 | 2023-2025 | Xolair |
| Pfizer INC. | $108.92 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $102.67 | 2019-2024 | Xywav |
| Medtronic, INC. | $73.58 | 2023-2024 | Novapak, Propel |
| Hikma Pharmaceuticals USA | $69.69 | 2024 | Ryaltris |
| Zoll Respicardia, INC. | $68.91 | 2024 | Remede System |
| Acclarent, INC | $68.27 | 2019-2020 | |
| Kaleo, INC. | $64.34 | 2019-2024 | Auvi-Q |
| Integra Lifesciences Corporation | $61.81 | 2024-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $55.50 | 2022-2025 | |
| Harmony Biosciences LLC | $53.42 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.29 | 2020-2024 | Cuvitru |
| Axsome Therapeutics, INC. | $50.76 | 2023-2024 | Sunosi |
| Intersect Ent, INC. | $39.97 | 2019-2020 | |
| Csl Behring | $34.84 | 2024-2025 | Hizentra |
| Grifols USA, LLC | $28.48 | 2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $23.60 | 2021 | |
| Merck Sharp & Dohme LLC | $23.18 | 2023 | |
| Acelrx Pharmaceuticals, INC. | $19.41 | 2020 | |
| Amgen INC. | $18.14 | 2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $18.03 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.66 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.69 | 2025 | Xhance |
| Alk-Abello, INC | $12.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Chitkara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.